ESPE Abstracts (2021) 94 P1-85

ESPE2021 ePoster Category 1 Pituitary A (10 abstracts)

Auxological and endocrine aspects in pediatric patients with type 1 Narcolepsy. Results of long-term follow-up in a pediatric endocrinology center

Valentina Assirelli 1 , Sara Casale 2 , Fabio Pizza 3,4 , Federico Baronio 5 , Giulio Di Donato 1 , Egidio Candela 1 , Antonio Balsamo 6 , Giuseppe Plazzi 4,7 & Alessandra Cassio 8

10 views


1Specialty School of Paediatrics - Alma Mater Studiorum, Università di Bologna, Bologna, Italy; 2University of Bologna, Program of Endocrine-Metabolic Diseases, Unit of Pediatrics, IRCCS- University Hospital of Bologna, Bologna, Italy; 3Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy; 4IRCCS Institute of Neurological Sciences of Bologna, Bellaria Hospital, AUSL of Bologna, Bologna, Italy; 5University of Bologna, Program of Endocrine-Metabolic Diseases, Unit of Pediatrics, IRCCS- Azienda Ospedaliero Universitaria Bologna, Bologna, Italy; 6University of Bologna, Program of Endocrine-Metabolic Diseases, Unit of Pediatrics, IRCCS-Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy; 7Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio-Emilia, Modena, Italy; 8University of Bologna, Program of Endocrine-Metabolic Diseases, Unit of Pediatrics, IRCCS-Azienda Ospedaliero Universitaria Bologna, Bologna, Italy


Introduction: Type 1 Narcolepsy is a rare pediatric condition characterized by central hypersomnia secondary to hypocretin deficiency. It can also involve the neuroendocrine axis, in particular determining obesity and central precocious puberty (CPP).

Objectives: The primary aim of this study is the evaluation of endocrine and auxological aspects at diagnosis and during follow-up in children affected with T1N, in treatment with Sodium Oxibate or not.

Methods: We retrospectively evaluated medical records of 98 consecutive patients affected with T1N during the period 2004-2020. We evaluated auxological, biochemical and radiological parameters for investigate endocrine-metabolic complications.

Results: 98 consecutive patients fulfilled inclusion criteria and were recruited for the study: 53 boys e 45 girls. Median follow up was 36 ± 16 months. Median age at diagnosis was 10,4 ± 3,2. At diagnosis we find a median height (SDS) of 0.6 ± 1.1 and BMI (SDS) of 1.1 ± 1.1. Overweight was reported in 25/97 (25.7%) and obesity in 33/97 (34%). A diagnosis of CPP was confirmed in 21/98 cases (21.4%) without significative gender differences. Treatment with GnRH agonist was necessary in 11/21 cases (52.3%). The other hormonal investigations were all within the limits of normality. Patients treated with Sodium Oxibate at 12 months of follow up were 46/98 (46.9%). After 36 months of follow up, we find a significative difference in BMI SDS between Sodium Oxibate treated vs untreated patients (0,0 ± 1,3 vs 1,3 ± 0,4) (P < 0.003). 62 patients reached their final height, with a median SDS of 0.5 ± 1.1 in boys and 0.3 ± 1.2 in girls. Target parental height was 0.2 ± 0.8 SDS in boys and 0.3 ± 0.7 in girls. There were no statistical differences between treated and untreated groups.

Conclusions: The results of our study confirm an increased frequency of CPP and obesity in T1N patients compared to general population. The treatment with Sodium Oxybate leads to an improvement of the BMI which also persist at 36 months of follow up. To our knowledge, these are the first results regarding the final height in a large series of patients diagnosed with T1N in pediatric age. IGF1 levels were in the normal range and stature SDS during follow-up and final height were in the range of parental target height.

Volume 94

59th Annual ESPE (ESPE 2021 Online)

Online,
22 Sep 2021 - 26 Sep 2021

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.